...
机译:大剂量依达比星联合Ara-C在复发或难治性急性淋巴细胞白血病患者中的药代动力学和临床研究
Department of Oncology/Hematology Division of Hematology Niguarda Ca’ Granda Hospital Piazza Ospedale Maggiore 3 20162 Milan Italy;
Department of Oncology/Hematology Division of Hematology Niguarda Ca’ Granda Hospital Piazza Ospedale Maggiore 3 20162 Milan Italy;
Department of Organic Chemistry University of Bologna Bologna Italy;
Department of Oncology/Hematology Division of Hematology Niguarda Ca’ Granda Hospital Piazza Ospedale Maggiore 3 20162 Milan Italy;
Department of Oncology/Hematology Division of Hematology Niguarda Ca’ Granda Hospital Piazza Ospedale Maggiore 3 20162 Milan Italy;
Department of Oncology/Hematology Division of Hematology Niguarda Ca’ Granda Hospital Piazza Ospedale Maggiore 3 20162 Milan Italy;
Department of Oncology/Hematology Division of Hematology Niguarda Ca’ Granda Hospital Piazza Ospedale Maggiore 3 20162 Milan Italy;
Department of Oncology/Hematology Division of Hematology Niguarda Ca’ Granda Hospital Piazza Ospedale Maggiore 3 20162 Milan Italy;
Department of Oncology/Hematology Division of Hematology Niguarda Ca’ Granda Hospital Piazza Ospedale Maggiore 3 20162 Milan Italy;
Department of Organic Chemistry University of Bologna Bologna Italy;
Department of Oncology/Hematology Division of Hematology Niguarda Ca’ Granda Hospital Piazza Ospedale Maggiore 3 20162 Milan Italy;
High-dose idarubicin; Pharmacokinetics; Acute lymphoblastic leukemia; Salvage regimen;
机译:米托蒽醌和Ara-C联合或不联合依托泊苷抢救化疗在成人复发或难治性急性淋巴细胞白血病中的临床疗效:韩国成人ALL工作组的回顾性多中心研究
机译:在成人和小儿急性淋巴细胞白血病中,单次大剂量的依达比星联合大剂量ARA-C(MSKCC ALL-3方案)。在罗马“ La Sapienza”大学的经历|血液学
机译:单药或与伊达比星和阿糖胞苷联用的反义寡核苷酸(ASO)LY2181308在难治性或复发性急性髓细胞性白血病(AML)患者中的安全性和药代动力学
机译:利用人工神经网络优化急性淋巴细胞白血病和急性髓性白血病样品的分类
机译:培养的人类免疫细胞,培养的人类急性淋巴细胞白血病细胞和急性粒细胞性白血病患者呼气中的挥发性生物标志物
机译:复发或难治性急性髓性白血病患者组合(OXA)组合(OXA)组合(OXA)的临床研究
机译:“单次大剂量依达比星联合大剂量ARA-C治疗儿童“高危”急性淋巴细胞白血病首次复发:AIEOP研究组